Seino, Y <br/><br/>
Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia).  [electronic resource] 

 -  Diabetes, obesity & metabolism  Oct 2012 
 - 910-7 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1463-1326 
<br/><br/><label>Standard No.: </label>10.1111/j.1463-1326.2012.01618.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Asian People<br/>Blood Glucose<br/>Body Mass Index<br/>Diabetes Mellitus, Type 2--blood<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Drug Administration Schedule<br/>Drug Therapy, Combination<br/>Female<br/>Glucagon-Like Peptide-1 Receptor<br/>Glycated Hemoglobin--metabolism<br/>Humans<br/>Hypoglycemia--blood<br/>Hypoglycemic Agents--administration & dosage<br/>Insulin--administration & dosage<br/>Japan--epidemiology<br/>Male<br/>Middle Aged<br/>Peptides--administration & dosage<br/>Philippines--epidemiology<br/>Postprandial Period<br/>Receptors, Glucagon--antagonists & inhibitors<br/>Republic of Korea--epidemiology<br/>Sulfonylurea Compounds--administration & dosage<br/>Taiwan--epidemiology<br/>Treatment Outcome